MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

45.91 +10.02 (+27.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,234,907
Open 41.07
Bid (Size) 45.85 (3)
Ask (Size) 46.00 (1)
Prev. Close 35.89
Today's Range 39.99 - 46.94
52wk Range 24.10 - 62.53
Shares Outstanding 54,026,103
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder
On Thursday, the U.S. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million. 
Via Benzinga

Performance

YTD
-10.9%
-10.9%
1 Month
+51.0%
+51.0%
3 Month
+53.2%
+53.2%
6 Month
+32.2%
+32.2%
1 Year
-9.2%
-9.2%

More News

Read More
Friday's session: gap up and gap down stocks
Via Chartmill
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move
Via Stocktwits
Earnings Scheduled For August 7, 2025
Via Benzinga
Assessing Crinetics Pharmaceuticals: Insights From 4 Financial Analysts
Via Benzinga
Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism
Via Investor's Business Daily
Topics Artificial Intelligence
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Tuesday's pre-market session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics (CRNX) Q2 Revenue Jumps 150%
Via The Motley Fool
Topics Intellectual Property
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly
Via Benzinga
Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds
Via Stocktwits
Topics Government
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Crinetics Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Crinetics Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Crinetics Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Crinetics Pharmaceuticals, Inc. - Common Stock trade on?
Crinetics Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock is CRNX on the Nasdaq Stock Market
What is the current price of Crinetics Pharmaceuticals, Inc. - Common Stock?
The current price of Crinetics Pharmaceuticals, Inc. - Common Stock is 45.91
When was Crinetics Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Crinetics Pharmaceuticals, Inc. - Common Stock was at 09/26/25 04:00 PM ET
What is the market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock is 2.48B
How many shares of Crinetics Pharmaceuticals, Inc. - Common Stock are outstanding?
Crinetics Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story